Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys.
The complement system and B cell complement receptor 2 (CR2), specific for C component C3dg, play important roles in both the innate and adaptive immune response. We used hapten and protein conjugates of anti-CR2 mAbs as models for C3dg-opsonized antigens and immune complexes to examine the handling of and immune response to these reagents in mice and in non-human primates (NHP). Mice immunized and boosted i.v. with only 100 ng of Alexa 488 rat anti-mouse CR1/2 mAb 7G6 had strong IgG immune responses to the Alexa 488 hapten and to rat IgG, compared to very weak immune responses in mice treated with a comparable isotype control; larger doses of Alexa 488 mAb 7G6 did not increase the immune response. A vaccine constructed by cross-linking anthrax protective antigen to mAb 7G6 proved to be effective at low doses in generating sufficiently high titer serum IgG antibodies to neutralize anthrax lethal toxin in vitro and to protect mice from i.v. challenge with anthrax lethal toxin. When biotinylated HB135, a mouse mAb specific for human CR2, was injected i.v. into NHP, the probe manifested the same initial marginal zone B cell binding and subsequent localization to follicular dendritic cells as we have previously reported for comparable experiments in mice. Moreover, i.v. immunization of NHP with 1 microg/kg of Alexa 488 mAb HB135 promoted an IgG immune response to the Alexa 488 hapten and to mouse IgG. Taken together, these results demonstrate the efficacy of using anti-CR2 mAbs as antigen carriers for i.v. immunization with small amounts of antigens without adjuvant.
Whipple
Emily C
EC
Department of Biochemistry and Molecular Genetics, University of Virginia Health Sciences Center, Charlottesville, VA 22908, United States.
Ditto
Andrew H
AH
Shanahan
Ryan S
RS
Gatesman
Jeremy J
JJ
Little
Stephen F
SF
Taylor
Ronald P
RP
Lindorfer
Margaret A
MA
D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control; D022122:Anthrax Vaccines; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000917:Antibody Formation; D017951:Antigen Presentation / Q000276:immunology; D007114:Immunization / Q000379:methods*; D007074:Immunoglobulin G / Q000276:immunology*; D008252:Macaca fascicularis; D051379:Mice; D008807:Mice, Inbred BALB C; D051381:Rats; D017464:Receptors, Complement 3d / Q000276:immunology*
D022122:Anthrax Vaccines; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D017464:Receptors, Complement 3d